EsoCap AG today announced the issue, by the Patent and Trademark Office, of a patent in Australia under no. 2015371725, based on patent application no. 2017132866/04 (057778). The patent is…
EsoCap AG hosted a well-attended virtual Investigators’ Meeting for the ACESO study on March 18, 2021. ACESO is a randomized, placebo-controlled, double-blind trial evaluating the efficacy, tolerability and safety of…
EsoCap AG organized a scientific advisory board meeting with eleven international experts in Eosinophilic Esophagitis (EoE) in a digital format on December 1, 2020. Three distinguished experts gave keynote presentations…
EsoCap AG has announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 10,744,095 on August 18, 2020. The patent is directed at the smart application…
EsoCap has announced that scientists from the University of Greifswald published exciting data demonstrating that a novel drug delivery technology enables targeted and long-lasting local therapy of the esophagus for…
EsoCap AG announced today that the Japanese Patent and Trademark Office issued a patent under number 6719471 on June 18, 2020, based on international patent PCT/EP2015/002601. The patent is directed…
EsoCap has announced that Dr Jacques Gonella has been appointed to the Company’s Board of Directors. “I am delighted to welcome Jacques Gonella to the EsoCap Board,” said Dr Werner…
EsoCap AG has been recognised by Pharma Tech Outlook as a top drug discovery and development solution provider in Europe for 2020. “We are extremely pleased to have been chosen…
EsoCap AG announced today that the Russia Patent and Trademark Office issued a patent under number 2714882 on February 20, 2020, based on patent application no. 2017132866/04(057778). The patent is…
EsoCap has been selected as a finalist to present at the RESI Europe 2020 Innovation Challenge from 200+ companies. The RESI (Redefining Early Stage Investment) conference series was created to…
Malzgasse 9, CH-4052 Basel
